Randomized phase II study of SOX+B-mab versus SOX+C-mab in patients with previously untreated recurrent advanced colorectal cancer with wild-type KRAS (MCSGO-1107 study)

Overview of attention for article published in BMC Cancer, August 2021

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (83rd percentile)
High Attention Score compared to outputs of the same age and source (93rd percentile)

Mentioned by

news: 1 news outlet

twitter: 1 X user

Citations

dimensions_citation: 5 Dimensions

Readers on

mendeley: 18 Mendeley

Summary News X Dimensions citations

So far, Altmetric has seen 1 news story.

SOX+bevacizumab or cetuximab combo offers similar benefits in recurrent advanced CRC (of 11)

Pediatric News , 18 Sep 2021

Key clinical point: The combination of S-1 and oxaliplatin (SOX) with bevacizumab (B-mab) or cetuximab (C-mab) had almost…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.